Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 5/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249301 | 0.81 | TRPV1 (0.36) | ALDH1A1TRPV1AROGAVEGFA | |
| SCHEMBL20249352 | 0.81 | TRPV1 (0.39) | TRPV1OGAVEGFAEGLN1KDM4E | |
| SCHEMBL20249395 | 0.78 | OGA (0.39) | TRPV1AROGARETPANK3 | |
| SCHEMBL20249351 | 0.78 | TRPV1 (0.38) | TRPV1AROGARETVEGFA | |
| SCHEMBL20249151 | 0.78 | GAA (0.47) | POLBALDH1A1LMNATSHRKMT2A | |
| SCHEMBL20249320 | 0.78 | OGA (0.39) | ALDH1A1KMT2ATRPV1OGARET | |
| SCHEMBL18291765 | 0.78 | PANK3 (0.34) | POLBALDH1A1ARPANK3KDM4E | |
| SCHEMBL20249268 | 0.77 | HRH4 (0.51) | ALDH1A1KDM4E | |
| SCHEMBL20249387 | 0.76 | OGA (0.42) | TRPV1OGAPANK3 | |
| SCHEMBL20249349 | 0.76 | DRD2 (0.43) | KMT2ATRPV1OGARETPANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | POLB 1145/4885ALDH1A1 944/4885LMNA 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.